Led and, developed through coaching, a diverse team of 8 sales representatives in Texas and Louisiana who were responsible for sales of Xolair in the Allergy and Pulmonology therapeutic areasLeveraged experiences in other therapeutic areas and insights from my team to build division priorities in Allergy and Pulmonology that drove a nation leading 75.8% Xolair market-share in 2019Utilizing a strategic approach focused on improving the customer experience that yielded 10.5% year over year growth and a Sales Excellence award (top 15%) in 2018Collaborated with contracting and senior leadership to develop impactful innovative solutions to cross portfolio issues including Genentech’s first Fee-For-Service program with Alternate Infusion CentersIdentified and alerted Xolair leadership on the opportunities/potential risks associated with the entry of Infusion Management Companies to the allergy marketplace, helping drive the cross portfolio need for future Work Product Teams focused on innovative approaches to this customer segment

Provided operational support for the Rituxan Immunology Clinical Specialist (RICS) leadership team: a team focused on driving sales of Rituxan in the GPA/MPA and the Rheumatoid Arthritis indications in the Nephrology and Rheumatology specialtiesDemonstrated a growth mindset, initiative, and strong work ethic in a new, undefined role that resulted in helping Rituxan achieving its 2017 sales forecastLeveraged prioritization, collaboration, and communication to successfully navigate a complex network of touchpointsServed as an interim DM for WEST RICS for three months • Built the cultural foundation of a newly formed team in a time of change• Sharpened skills of team members by executing field rides, providing differentiated, growth-oriented coaching and feedback, and assessing behavior Built and executed various projects “on demand” to support needs of RICS team including:• Creation, communication and calibration of RICS MBO’s • Sales contests and presentations on strategies/philosophy

Sold Rituxan to Nephrologists in Texas, Oklahoma, and New Mexico in an orphan patient population of GPA/MPA, achieving representative of the Year in 2014Excelled in an ambiguous role that required innovative approaches to trainings, targeting, and tactics, achieving Sales Excellence (top 15%) in 2016 and 2015Recognized as 2016 Nephrology Foundation Award winner for self-directed, wholistic approach to building out and delivering of the Infusion Locator Project Awards:2016 Nephrology Sales Excellence award (250% obtainment of goal)2016 Nephrology Sustained Performance Award (250% obtainment of goal 2 of 3 years)2016. Nephrology Impact and Innovation Award2015 Nephrology Sales Excellence award (250% obtainment of goal)2015 Nephrology West Team MVP (peer vote)2014 Nephrology Rep of the year2014 Nephrology West Team MVP (peer vote)

Responsible for sales of Krystexxa, a PEGylated uric acid specific enzyme administrated by intravenous infusion for the treatment of chronic gout in adult patients refractory to conventional therapy. Targets include rhuematologists, infusion centers, and hospital outpatient infusion departments in central and south Texas. Responsiblities include the launch of a new IV product, execution of sales in a buy and bill environment, facilitation of specialty pharmacy utilization, and customer support in a "start up" company enviroment.

Quickly learned a new market place, and implemented a strategy to improve Rituxan sales in the rheumatoid arthritis marketplace in the Rheumatology spacePrimary customers include rheumatologists, infusion centers, and hospital infusion centers in Georgia. Due to the “buy and bill” nature of Rituxan, duties require a focus on project selling to prescribing physicians, purchasers, infusion nurses, benefits investigations, prior authorization coordinators, and reimbursement coordinators. Demonstrated ability to quickly learn a new market place, sustain current Rituxan sales, and implement a strategy to move territory from sustaining to achieving-YTD immunology dominate account: 105% of goal (Region 119%, Nation 105%)-YTD oncology/immunology mixed: 100% (Region 112%, Nation 103%)Immediate impact on sales demonstrated in sales data-Immunology dominate acct 3 month growth: 34.6% vs. LY (Region 43.3%, Nation 13%)-Weekly sales summary projects 120.6% to plan through August for immunology dominate accts.-Weekly sales summary projects 121.5% to plan through August for mixed accts.

Sales representative in the Injectable Sales Group:Portfolio included:• Hylgan: Injection for osteoarthritis• Eligard: Injection for treatment of prostate cancer• Lovenox: Anti-coagulant for prevention of DVTFocused on selling product in the arenas of "buy and bill" and speciality pharmacy medicine for managed care and medicare plan B patientsDaily activity included driving sales, taking orders for product, working with office staff on specialty pharmacy requests, utilization of patient assistance programs, and implementation of various patient education programsLed West region in sales growth through May 2009• Ranked 1st out of 52 in Eligard sales growth• Ranked 8th out of 52 in Hyalgan sales growth2008 US Sales Champions - Regional Trip winner• Ranked 7th out of 106 representatives in overall sales• Obtained 100% achievement of goal for product portfolio in 2007• Obtained 100.7% of goal for product portfolio in 2006Institutional sales representative:Portfolio consists of the following products • Plavix: anti-platelet • Avapro/Avalide: anti-hypertensive• Ambien: hypnotic• Rilutek: treatment for ALS• Ambien CR: Hypnotic• Arixtra: anti-coagulant• Primacor: treatment of congested heart failurePrimary customers include cardiologists, orthopedic surgeons, rheumatologists, neurologists, internal medicine physicians, psychiatrists, and hospitalists2005 Sales Champions Regional Award trip winner: Ranked as high as 3rd out of 165 Central Nervous System representatives• Ranked 1st out of 159 in Ambien sales in nation in 2004• Ranked 1st out of 173 in Avapro sales in nation in 2003